Clinical Trials Browser

Sarcoma, Alveolar Soft Part

Somatostatinoma

Thyroid Cancer, Papillary, Thyroid Neoplasms, Adenocarcinoma, Follicular, Carcinoma, Medullary

Carcinoma, Renal Cell

Gastrointestinal Stromal Tumors

Carcinoma, Renal Cell

Carcinoma, Renal Cell

Carcinoma, Non-Small-Cell Lung, Thymoma, Small Cell Lung Carcinoma

Thymoma, Thymus Neoplasms

Breast Neoplasms, Breast Neoplasms, Male

Carcinoma, Renal Cell

Carcinoma, Renal Cell, Kidney Neoplasms

Breast Neoplasms, Neoplasm Metastasis

Carcinoma, Renal Cell, Neoplasm Metastasis

Paraganglioma

Stomach Neoplasms

Carcinoma, Renal Cell

Carcinoma, Non-Small-Cell Lung

Small Cell Lung Carcinoma

Clear-cell metastatic renal cell carcinoma

Carcinoma, Renal Cell, Kidney Neoplasms

Carcinoma, Renal Cell

Carcinoma, Renal Cell

Thyroid Cancer, Papillary, Thyroid Neoplasms, Adenocarcinoma, Follicular

Pancreatic Neuroendocrine Tumour Metastatic

Carcinoma, Renal Cell, Kidney Neoplasms, Urogenital Neoplasms

Ovarian Neoplasms

Endometrial Adenocarcinoma

Uveal Melanoma, Melanoma, Neoplasm Metastasis

Carcinoma, Renal Cell

Urinary Bladder Neoplasms

Breast Neoplasms, Breast Neoplasms, Male, Inflammatory Breast Neoplasms

Nasopharyngeal Carcinoma, Neoplasm Metastasis

Urinary Bladder Neoplasms

Gastrointestinal Stromal Tumors

Neoplasm Metastasis

Colorectal Neoplasms

Neoplasm Metastasis, Recurrence, Thymoma

Gastro Intestinal Stromal Tumor

Lung Neoplasms

Urinary Bladder Neoplasms, Urethral Neoplasms

Prostatic Neoplasms

Carcinoma, Non-Small-Cell Lung

Carcinoma, Renal Cell

Myelodysplastic Syndromes, Leukemia, Myelomonocytic, Chronic

Fallopian Tube Neoplasms, Ovarian Neoplasms

Adenocarcinoma Of Esophagus, Esophageal Neoplasms

Ovarian Neoplasms, Adenocarcinoma, Clear Cell

Carcinoma, Renal Cell

Clear-cell metastatic renal cell carcinoma

Clinical Trials

Sunitinib or Cediranib for Alveolar Soft Part Sarcoma

OCCLURANDOM

Sunitinib Malate in Treating Patients With Thyroid Cancer That Did Not Respond to Iodine I 131 and Cannot Be Removed by Surgery

Pazopanib Versus Sunitinib in the Treatment of Asian Subjects With Locally Advanced and/or Metastatic Renal Cell Carcinoma

A Study to Assess DCC-2618 and Sunitinib in Patients With Advanced GIST After Treatment With Imatinib

Testing Cabozantinib, Crizotinib, Savolitinib and Sunitinib in Kidney Cancer Which Has Progressed

ASSET

Molecular Profiling and Targeted Therapy for Advanced Non-Small Cell Lung Cancer, Small Cell Lung Cancer, and Thymic Malignancies

Sunitinib for Advanced Thymus Cancer Following Earlier Treatment

Sunitinib in Treating Patients With Newly Diagnosed Stage II or Stage III Breast Cancer That Can Be Removed by Surgery

Phase II Study of Alternating Sunitinib and Temsirolimus

Sunitinib Malate With or Without Gemcitabine Hydrochloride in Treating Patients With Advanced Kidney Cancer That Cannot Be Removed By Surgery

SU11248 as Consolidation After Response to Taxanes in Metastatic Breast Cancer

MERECA

FIRSTMAPPP

Exploratory Study of Drug Sensitivity Prediction Software (IRCR-DReSS) With Patient-derived Tumor Cells of Metastatic Gastric Cancer

Trebananib With or Without Bevacizumab, Pazopanib Hydrochloride, Sorafenib Tosylate, or Sunitinib Malate in Treating Patients With Advanced Kidney Cancer

Pemetrexed and/or Sunitinib as Second-Line Therapy in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer

Irinotecan, Carboplatin, and Sunitinib in First Line Extensive-Stage Small Cell Lung Cancer

BIONIKK

Sunitinib as First-Line Therapy in Treating Patients With Locally Advanced Metastatic Papillary Renal Cell Cancer

Cabozantinib-s-malate or Sunitinib Malate in Treating Patients With Previously Untreated Locally Advanced or Metastatic Kidney Cancer

INMUNOSUN

IIT Sutent

RESUNET

Sunitinib Scheduling in Metastatic Renal Cell Carcinoma (mRCC)

Sunitinib Malate in Treating Patients With Persistent or Recurrent Clear Cell Ovarian Cancer

Sunitinib Malate in Treating Patients With Recurrent or Metastatic Endometrial Cancer

SUAVE

FARETES

Sutent

Sunitinib Malate, Paclitaxel, Doxorubicin Hydrochloride, and Cyclophosphamide Before Surgery in Treating Patients With Stage IIB-IIIC Breast Cancer

Study Evaluating Two Loading Regimens of Sunitinib or Bevacizumab Alternating With Cisplatin and Gemcitabine as Induction Therapy for Locally Advanced Nasopharyngeal Carcinoma (NPC)

Sunitinib in Treating Patients With Locally Advanced Bladder Cancer

A Study of Sunitinib In Young Patients With Advanced Gastrointestinal Stromal Tumor

MetAction

FOLFIRI and Sunitinib in Metastatic Colorectal Cancer

KOSMIC

Masitinib in Patients With Gastro-Intestinal Stromal Tumour Resistant to Imatinib

Sunitinib in Never-Smokers With Lung Adenocarcinoma

Gemcitabine Hydrochloride, Cisplatin, and Sunitinib Malate as First-Line Therapy in Treating Patients With Locally Advanced And/or Metastatic Transitional Cell Carcinoma of the Urothelium (SUCCINCT)

Phase II Sunitinib Prog Met AIPC

Sunitinib Non Small Cell Lung Cancer Patients Over 70

Sunitinib Malate in Treating Patients With Previously Untreated Metastatic Kidney Cancer

Sunitinib in Treating Patients With Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia

Sunitinib in Recurrent and Refractory Ovarian, Fallopian Tube and Peritoneal Carcinoma

Capecitabine With or Without Sunitinib Malate as First-Line Therapy in Treating Patients With Metastatic Cancer of the Esophagus or Gastroesophageal Junction

Sunitinib® in Patients With Recurrent Ovarian Clear Cell Carcinoma

A Study of Famitinib in Patients With Advanced Metastatic Renal Cell Cancer

Study of Efficacy and Safety of Sunitinib Given on an Individualized Schedule